Pancreatic Cancer Early Detection Consortium (NCT04970056)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years to 90 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- Honor Health Research Institute — Scottsdale, Arizona
- Providence Health and Services — Burbank, California
- City of Hope — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Health — Los Angeles, California
- Hoag — Newport Beach, California
- UC Irvine Health — Orange, California
- UC Davis — Sacramento, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Yale University — New Haven, Connecticut
- Mayo Clinic Jacksonville — Jacksonville, Florida
- University of Miami — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- Emory University Hospital — Atlanta, Georgia
- Illinois CancerCare — Bloomington, Illinois
- University of Chicago Medicine — Chicago, Illinois
- NorthShore University HealthSystem — Evanston, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Umass Memorial Medical Center — Worcester, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Beaumont/Corewell Health — Royal Oak, Michigan
- University of Nebraska Medical Center — Omaha, Nebraska
📞 Contact the Study Coordinator
Phone: (734) 665-4108
Email: naveen.fawaz@arborresearch.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreas Cancer
- Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma — St Louis, Missouri
- A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. — Houston, Texas
- A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma — Los Angeles, California
- Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement — Irvine, California
- A Supervised Prehabilitation Program for Patients With Pancreatic Cancer — Los Angeles, California
- Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial — Toronto, Ontario
Explore by condition: All Pancreas Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.